April 3, 2020 10:34 AM EDT

GSK's asthma biologic Nucala is one step closer to approval in key chronic rhinosinusitis population

Natalie Grover

Reporter

Months after GSK’s Nucala cleared in a pivotal rare blood disorder study, the asthma biologic has scored in a late-stage trial in chronic rhinosinusitis …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

GSK's asthma biologic Nucala is one step closer to approval in key chronic rhinosinusitis population

Natalie Grover

Reporter

Sign up to read this article for free.

Updated: Flagship gene therapy startup Ring Therapeutics nearly halves workforce as CEO departs

Novartis turns to BioAge for new targets based on longevity and exercise

Merck’s long-awaited obesity move is an oral GLP-1 from China

In surprise move, FDA's No. 2 Bumpus to leave agency at end of 2024

Post-Hoc: Biosecure is dead. Long live Biosecure?

US spent $450B on drugs last year, CMS says, with new obesity and diabetes drugs adding to total

GSK's asth­ma bi­o­log­ic Nu­cala is one step clos­er to ap­proval in key chron­ic rhi­nos­i­nusi­tis pop­u­la­tion

Natalie Grover

Reporter

Sign up to read this article for free.

more like this

Up­dat­ed: Flag­ship gene ther­a­py start­up Ring Ther­a­peu­tics near­ly halves work­force as CEO de­parts

No­var­tis turns to BioAge for new tar­gets based on longevi­ty and ex­er­cise

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

In sur­prise move, FDA's No. 2 Bum­pus to leave agency at end of 2024

Post-Hoc: Biose­cure is dead. Long live Biose­cure?

US spent $450B on drugs last year, CMS says, with new obe­si­ty and di­a­betes drugs adding to to­tal

GSK's asthma biologic Nucala is one step closer to approval in key chronic rhinosinusitis population

Updated: Flagship gene therapy startup Ring Therapeutics nearly halves workforce as CEO departs

Novartis turns to BioAge for new targets based on longevity and exercise

Merck’s long-awaited obesity move is an oral GLP-1 from China

In surprise move, FDA's No. 2 Bumpus to leave agency at end of 2024

Post-Hoc: Biosecure is dead. Long live Biosecure?

US spent $450B on drugs last year, CMS says, with new obesity and diabetes drugs adding to total